Table 2.
Blood markers in hospitalized patients with acute ischemic stroke.
| COVID-19 (+) | COVID-19 (-) | |||
|---|---|---|---|---|
| N | 37 | 355 | P | |
| Blood markers (studied in all) | ||||
| C-reactive protein | 9.32±9.96 | 3.93±7.31 | <0.001 | |
| Procalcitonin | 4.51±16.89 | 1.24±7.78 | 0.054 | |
| Erythrocyte sedimentation rate | 40±29 | 25±22 | 0.001 | |
| Activated partial thromboplastin time | 25.49±5.23 | 26.29±16.2 | 0.765 | |
| Prothrombin time (as INR) | 1.31±0.41 | 1.17±0.41 | 0.055 | |
| D-dimer | 5.27±6.58 | 4.33±10.04 | 0.585 | |
| Fibrinogen | 460±186 | 365±140 | 0.005 | |
| Ferritin | 456±497 | 158±683 | 0.015 | |
| Platelet | 229±101 | 229±101 | 0.701 | |
| Hemoglobin | 12.16±2.84 | 12.93±2.38 | 0.067 | |
| Lymphocyte count | 1.09±0.68 | 1.81±1.15 | <0.001 | |
| Leukocyte count | 10.81±3.7 | 9.36±4.07 | 0.039 | |
| Homocysteine | 19.4±9.05 | 15.9±10.65 | 0.121 | |
| Blood markers (studied in selected cases) | ||||
| Anti Nuclear Antigen | Studied | 70% | 12% | |
| Positive | 42% | 34% | 0.721 | |
| Anti-dsDNA Antibody | Studied | 70% | 11% | |
| Positive | 0% | 6% | 0.221 | |
| ENA Panel | Studied | 70% | 11% | |
| Positive | 0% | 0% | - | |
| Anti-phospholipid antibody | Studied | 70% | 26% | |
| Positive | 0% | 17% | 0.023 | |
| Factor V Leiden | Studied | 56% | 6.5% | |
| Heterozygous | 10% | 9% | 0.957 | |
| Prothrombin G20210A mutation | Studied | 56% | 7.2% | |
| Heterozygous | 0% | 12% | 0.148 | |
| MTHFR C677T polymorphism | Studied | 56% | 7.2% | |
| Heterozygous | 29% | 52% | 0.076 | |
| Homozygous | 10% | 0% | ||
| MTHFR A1298C polymorphism | Studied | 56% | 7.2% | |
| Heterozygous | 24% | 39% | 0.206 | |
| Homozygous | 0% | 6% | ||
| PAI-1 gene polymorphism | Studied | 56% | 7.2% | |
| Heterozygous | 19% | 40% | 0.002 | |
| Homozygous | 5% | 27% | ||
| 4G/4G | 38% | 30% | 0.780 | |
| 4G/5G | 19% | 46% | ||
| 5G/5G | 43% | 24% | ||
| Factor VIII | Studied | 26% | 26% | |
| Average | 265±135 | 248±91 | ||
| Factor V | Studied | 21% | 5% | |
| Average | 109±16 | 105±18 | ||
| FactorX | Studied | 21% | 5% | |
| Average | 76±25 | 94±28 | ||
| FactorXIII | Studied | 21% | 5% | |
| Average | 87±23 | 99±33 | ||
Abbreviations: MTHFR: Methylenetetrahydrofolate reductase; PAI: Plasminogen activator inhibitor.